Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.
Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback